Hypoxic preconditioned aged BMSCs accelerates MI injury repair by modulating inflammation, oxidative stress and apoptosis

Song, Hui‐Fang; Li, Bin; Guo, Rui; He, Sheng; Peng, Zexu; Qu, Junyuan; Zhao, Yunhe; Zhai, Xiaoyan; Wu, Yin; Yang, Kun; Fan, Xing; Zhang, Jie; Tan, Jia-Yin; Liu, Yang; Xie, Jiemin; Xu, Jun

doi:10.1016/j.bbrc.2022.08.039

Cited by 6 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the EXO released from MSCs under normoxic conditions in vitro and under hypoxic conditions in vivo carry different biological molecules with correspondingly different therapeutic effects. It has been reported that transplantation of MSCs under hypoxic conditions results in an enhanced therapeutic effect for MI [103,104], indicating that hypoxic preconditioning may be a potential approach to prime MSC-EXO for MI treatment. Accumulating evidence shows that EXO from hypoxia-primed MSCs used to treat MI are superior to EXO from MSCs cultured under normoxic conditions [63,105,106].…”

Section: Msc-exo Generated From Different Culture Conditionsmentioning

confidence: 99%

Mesenchymal Stem Cell-Derived Exosomes for Myocardial Infarction Treatment

Zheng¹,

Hong²,

Hu³

et al. 2023

Exosomes - Recent Advances From Bench to Bedside

View full text Add to dashboard Cite

Myocardial infarction (MI) is a major cause of morbidity and mortality in modern society. Over the past decades, mesenchymal stem cell (MSCs)-based therapy has shown promising results in the treatment of MI due to their unique properties of multi-differentiation ability, immune-privileged phenotype and paracrine activity. Recently, MSC-derived exosomes (MSC-EXO) have been proposed as a promising therapeutic strategy for MI with their ability to inhibit cardiomyocyte apoptosis and stimulate vascular angiogenesis. They also aid immunoregulation and rejuvenation of cardiomyocyte senescence by transporting their unique content such as proteins, lipids, and miRNAs. Compared with MSC transplantation, MSC-EXO administration has shown several advantages, including lower toxicity and immunogenicity and no risk of tumor formation. Nonetheless the potential mechanisms underlying MSC-EXO-based therapy for MI are not fully understood. In addition, lack of modification of MSC-EXOs can impact therapeutic efficacy. It is vital to optimize MSC-EXO and enhance their therapeutic efficacy for MI. We summarize the recent advances regarding biological characteristics, therapeutic potential and mechanisms, and optimal approaches to the use of MSC-EXOs in the treatment of MI.

show abstract

Section: Msc-exo Generated From Different Culture Conditionsmentioning

confidence: 99%

Mesenchymal Stem Cell-Derived Exosomes for Myocardial Infarction Treatment

Zheng¹,

Hong²,

Hu³

et al. 2023

Exosomes - Recent Advances From Bench to Bedside

View full text Add to dashboard Cite

show abstract

“…1). Many studies have found that MSCT significantly reduce the apoptosis of diseases-related tissue cells (Table 1), which is achieved by the activation of a variety of signaling pathways [13][14][15]. More interestingly, MSCs also alleviate diseases by promoting apoptosis in some cells, such as autoimmune diseases and tumors [16][17][18].…”

Section: Introductionmentioning

confidence: 99%

The dual role of mesenchymal stem cells in apoptosis regulation

Chen,

Xia,

Yao

et al. 2024

Cell Death Dis

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are widely distributed pluripotent stem cells with powerful immunomodulatory capacity. MSCs transplantation therapy (MSCT) is widely used in the fields of tissue regeneration and repair, and treatment of inflammatory diseases. Apoptosis is an important way for tissues to maintain cell renewal, but it also plays an important role in various diseases. And many studies have shown that MSCs improves the diseases by regulating cell apoptosis. The regulation of MSCs on apoptosis is double-sided. On the one hand, MSCs significantly inhibit the apoptosis of diseased cells. On the other hand, MSCs also promote the apoptosis of tumor cells and excessive immune cells. Furthermore, MSCs regulate apoptosis through multiple molecules and pathways, including three classical apoptotic signaling pathways and other pathways. In this review, we summarize the current evidence on the regulation of apoptosis by MSCs.

show abstract

“…The decline in ovarian function in women after menopause leads to a decrease in estrogen levels and changes in hormone levels (sensitivity), such as calcitonin and parathyroid hormones. In patients with senile osteoporosis, bone marrow-derived mesenchymal stem cells age, their regenerative ability is weakened, their growth cycle is stagnated, and their level of osteogenic differentiation is reduced, resulting in changes in the bone microstructure and aging of extramedullary tissues [1][2][3]. Due to an increasingly large elderly population, the number Pharmaceuticals 2023, 16, 1438 2 of 15 of people with osteoporosis has increased to approximately 200 million globally [4].…”

Section: Introductionmentioning

confidence: 99%

Morroniside Inhibits Inflammatory Bone Loss through the TRAF6-Mediated NF-κB/MAPK Signalling Pathway

Xiao,

Han,

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Osteoporosis is a chronic inflammatory disease that severely affects quality of life. Cornus officinalis is a Chinese herbal medicine with various bioactive ingredients, among which morroniside is its signature ingredient. Although anti-bone resorption drugs are the main treatment for bone loss, promoting bone anabolism is more suitable for increasing bone mass. Therefore, identifying changes in bone formation induced by morroniside may be conducive to developing effective intervention methods. In this study, morroniside was found to promote the osteogenic differentiation of bone marrow stem cells (BMSCs) and inhibit inflammation-induced bone loss in an in vivo mouse model of inflammatory bone loss. Morroniside enhanced bone density and bone microstructure, and inhibited the expression of IL6, IL1β, and ALP in serum (p < 0.05). Furthermore, in in vitro experiments, BMSCs exposed to 0–256 μM morroniside did not show cytotoxicity. Morroniside inhibited the expression of IL6 and IL1β and promoted the expression of the osteogenic transcription factors Runx2 and OCN. Furthermore, morroniside promoted osteocalcin and Runx2 expression and inhibited TRAF6-mediated NF-κB and MAPK signaling, as well as osteoblast growth and NF-κB nuclear transposition. Thus, morroniside promoted osteogenic differentiation of BMSCs, slowed the occurrence of the inflammatory response, and inhibited bone loss in mice with inflammatory bone loss.

show abstract

Hypoxic preconditioned aged BMSCs accelerates MI injury repair by modulating inflammation, oxidative stress and apoptosis

Cited by 6 publications

References 38 publications

Mesenchymal Stem Cell-Derived Exosomes for Myocardial Infarction Treatment

Mesenchymal Stem Cell-Derived Exosomes for Myocardial Infarction Treatment

The dual role of mesenchymal stem cells in apoptosis regulation

Morroniside Inhibits Inflammatory Bone Loss through the TRAF6-Mediated NF-κB/MAPK Signalling Pathway

Contact Info

Product

Resources

About